surmount-1 tirzepatide weight loss percent nejm 2022 Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Trial Semaglutide vs. Tirzepatide: Which GLP-1

Weight loss itself provides immediate cardiac benefits when achieved through tirzepatide therapy

Accessed 16 July 2021 Graveling AJ, Frier BM (2015) Driving and diabetes: problems, licensing restrictions and recommendations for safe driving

You might notice some of your clothes fit differently now, which can also be a sign of weight loss

Based on clinical trial data: Common: Nausea (22-40%most common complaint) Flushing (14-17%) Headache (9-14%) Injection site reactions Less common: Vomiting Fatigue Dizziness Serious concerns: Transient blood pressure increases Hyperpigmentation with frequent use Contraindicated in uncontrolled hypertension or cardiovascular disease The nausea can be dose-limiting for some individuals

Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

10.3390/ph17020199 5 ArdJ.FitchA.FruhS.HermanL